Carbon Dioxide → (S)-1-(5-BOC-aminomethyl-1,2,4-oxadiazol-3-yl)-8-chloro-11,12,13,13a-tetrahydro-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepin-9-one
反応式
[C:1](NCC(O)=O)([O:3][C:4]([CH3:7])([CH3:6])[CH3:5])=[O:2].[C:13](N1C=CN=C1)([N:15]1C=CN=C1)=O.[C:25](=O)=O.[Cl:28][C:29]1[C:34]2[C:35](=[O:50])[N:36]3[CH2:49][CH2:48][CH2:47][C@H:37]3[C:38]3[N:39]([CH:40]=[N:41][C:42]=3[C:43](=[N:45][OH:46])[NH2:44])[C:33]=2[CH:32]=[CH:31][CH:30]=1>CN(C)C=O>[C:1]([C:25]1[O:46][N:45]([CH2:13][NH2:15])[CH:43]([C:42]2[N:41]=[CH:40][N:39]3[C:33]4[CH:32]=[CH:31][CH:30]=[C:29]([Cl:28])[C:34]=4[C:35](=[O:50])[N:36]4[CH2:49][CH2:48][CH2:47][C@H:37]4[C:38]=23)[N:44]=1)([O:3][C:4]([CH3:5])([CH3:6])[CH3:7])=[O:2]参加物
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
4.16 g (23.6 mmol) of BOC-glycine were dissolved in 30 ml of N,N-dimethylformamide and treated portionwise with 4.08 g (25.2 mmol) of 1,1'-carbonyldiimidazole. After completion of the CO2 evolution the solution was stirred at 50° for 20 min. Then, 7.36 g (22.2 mmol) of (S)-8-chloro-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxamidoxime were added and the mixture was stirred at 90° overnight. The reaction mixture was evaporated, the residue was dissolved in methylene chloride and the solution was washed once with water and once with saturated sodium bicarbonate solution. After drying and concentrating there were obtained 7.75 g (74%) of (S)-1-(5-BOC-aminomethyl-1,2,4-oxadiazol-3-yl)-8-chloro-11,12,13,13a-tetrahydro-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepin-9-one, which was used in the next step without further purification.
後処理
- customThe reaction mixture was evaporated
- dissolutionthe residue was dissolved in methylene chloride
- washthe solution was washed once with water and once with saturated sodium bicarbonate solution
- customAfter drying
- concentrationconcentrating there
出典と根拠
- ORDレコード
- ord-29b2512cfa6d4f9cb14e4890860d52ed
- 出典データセット
- uspto-grants-1997_09
- 特許番号
- US05665718
反応ノート
読み込み中…